High MMP-9 activity levels in fragile X syndrome are lowered by minocycline

Magdalena Dziembowska, Dalyir I. Pretto, Aleksandra Janusz, Leszek Kaczmarek, Mary Jacena Leigh, Nielsen Gabriel, Blythe Durbin-Johnson, Randi J Hagerman, Flora Tassone

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by lack of the FMR1 protein, FMRP, a translational repressor. Its absence leads to up-regulation of locally translated proteins involved in synaptic transmission and plasticity, including the matrix metalloproteinase-9 (MMP-9). In the Fmr1 knock-out (KO), a mouse model of FXS, an abnormal elevated expression of MMP-9 in the brain was pharmacologically down-regulated after treatment with the tetracycline derivative minocycline. Moreover, the rescue of immature dendritic spine morphology and a significant improvement of abnormal behavior were associated with down-regulation of MMP-9. Here, we report on high plasma activity of MMP-9 in individuals with FXS. In addition, we investigate MMP-9 changes in patients with FXS who have gone through a minocycline controlled clinical trial and correlate MMP-9 activity to clinical observations. The results of this study suggest that, in humans, activity levels of MMP-9 are lowered by minocycline and that, in some cases, changes in MMP-9 activity are positively associated with improvement based on clinical measures.

Original languageEnglish (US)
Pages (from-to)1897-1903
Number of pages7
JournalAmerican Journal of Medical Genetics, Part A
Volume161
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Fragile X Syndrome
Minocycline
Matrix Metalloproteinase 9
Fragile X Mental Retardation Protein
Dendritic Spines
Neuronal Plasticity
Controlled Clinical Trials
Tetracycline
Human Activities
Knockout Mice
Synaptic Transmission
Up-Regulation
Down-Regulation
Brain

Keywords

  • FXS
  • Metalloproteinases
  • Minocycline
  • MMP-9

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., ... Tassone, F. (2013). High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. American Journal of Medical Genetics, Part A, 161(8), 1897-1903. https://doi.org/10.1002/ajmg.a.36023

High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. / Dziembowska, Magdalena; Pretto, Dalyir I.; Janusz, Aleksandra; Kaczmarek, Leszek; Leigh, Mary Jacena; Gabriel, Nielsen; Durbin-Johnson, Blythe; Hagerman, Randi J; Tassone, Flora.

In: American Journal of Medical Genetics, Part A, Vol. 161, No. 8, 08.2013, p. 1897-1903.

Research output: Contribution to journalArticle

Dziembowska, M, Pretto, DI, Janusz, A, Kaczmarek, L, Leigh, MJ, Gabriel, N, Durbin-Johnson, B, Hagerman, RJ & Tassone, F 2013, 'High MMP-9 activity levels in fragile X syndrome are lowered by minocycline', American Journal of Medical Genetics, Part A, vol. 161, no. 8, pp. 1897-1903. https://doi.org/10.1002/ajmg.a.36023
Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. American Journal of Medical Genetics, Part A. 2013 Aug;161(8):1897-1903. https://doi.org/10.1002/ajmg.a.36023
Dziembowska, Magdalena ; Pretto, Dalyir I. ; Janusz, Aleksandra ; Kaczmarek, Leszek ; Leigh, Mary Jacena ; Gabriel, Nielsen ; Durbin-Johnson, Blythe ; Hagerman, Randi J ; Tassone, Flora. / High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. In: American Journal of Medical Genetics, Part A. 2013 ; Vol. 161, No. 8. pp. 1897-1903.
@article{5e53e30caf504edab09c49c45c56ced5,
title = "High MMP-9 activity levels in fragile X syndrome are lowered by minocycline",
abstract = "Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by lack of the FMR1 protein, FMRP, a translational repressor. Its absence leads to up-regulation of locally translated proteins involved in synaptic transmission and plasticity, including the matrix metalloproteinase-9 (MMP-9). In the Fmr1 knock-out (KO), a mouse model of FXS, an abnormal elevated expression of MMP-9 in the brain was pharmacologically down-regulated after treatment with the tetracycline derivative minocycline. Moreover, the rescue of immature dendritic spine morphology and a significant improvement of abnormal behavior were associated with down-regulation of MMP-9. Here, we report on high plasma activity of MMP-9 in individuals with FXS. In addition, we investigate MMP-9 changes in patients with FXS who have gone through a minocycline controlled clinical trial and correlate MMP-9 activity to clinical observations. The results of this study suggest that, in humans, activity levels of MMP-9 are lowered by minocycline and that, in some cases, changes in MMP-9 activity are positively associated with improvement based on clinical measures.",
keywords = "FXS, Metalloproteinases, Minocycline, MMP-9",
author = "Magdalena Dziembowska and Pretto, {Dalyir I.} and Aleksandra Janusz and Leszek Kaczmarek and Leigh, {Mary Jacena} and Nielsen Gabriel and Blythe Durbin-Johnson and Hagerman, {Randi J} and Flora Tassone",
year = "2013",
month = "8",
doi = "10.1002/ajmg.a.36023",
language = "English (US)",
volume = "161",
pages = "1897--1903",
journal = "American Journal of Medical Genetics",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - High MMP-9 activity levels in fragile X syndrome are lowered by minocycline

AU - Dziembowska, Magdalena

AU - Pretto, Dalyir I.

AU - Janusz, Aleksandra

AU - Kaczmarek, Leszek

AU - Leigh, Mary Jacena

AU - Gabriel, Nielsen

AU - Durbin-Johnson, Blythe

AU - Hagerman, Randi J

AU - Tassone, Flora

PY - 2013/8

Y1 - 2013/8

N2 - Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by lack of the FMR1 protein, FMRP, a translational repressor. Its absence leads to up-regulation of locally translated proteins involved in synaptic transmission and plasticity, including the matrix metalloproteinase-9 (MMP-9). In the Fmr1 knock-out (KO), a mouse model of FXS, an abnormal elevated expression of MMP-9 in the brain was pharmacologically down-regulated after treatment with the tetracycline derivative minocycline. Moreover, the rescue of immature dendritic spine morphology and a significant improvement of abnormal behavior were associated with down-regulation of MMP-9. Here, we report on high plasma activity of MMP-9 in individuals with FXS. In addition, we investigate MMP-9 changes in patients with FXS who have gone through a minocycline controlled clinical trial and correlate MMP-9 activity to clinical observations. The results of this study suggest that, in humans, activity levels of MMP-9 are lowered by minocycline and that, in some cases, changes in MMP-9 activity are positively associated with improvement based on clinical measures.

AB - Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by lack of the FMR1 protein, FMRP, a translational repressor. Its absence leads to up-regulation of locally translated proteins involved in synaptic transmission and plasticity, including the matrix metalloproteinase-9 (MMP-9). In the Fmr1 knock-out (KO), a mouse model of FXS, an abnormal elevated expression of MMP-9 in the brain was pharmacologically down-regulated after treatment with the tetracycline derivative minocycline. Moreover, the rescue of immature dendritic spine morphology and a significant improvement of abnormal behavior were associated with down-regulation of MMP-9. Here, we report on high plasma activity of MMP-9 in individuals with FXS. In addition, we investigate MMP-9 changes in patients with FXS who have gone through a minocycline controlled clinical trial and correlate MMP-9 activity to clinical observations. The results of this study suggest that, in humans, activity levels of MMP-9 are lowered by minocycline and that, in some cases, changes in MMP-9 activity are positively associated with improvement based on clinical measures.

KW - FXS

KW - Metalloproteinases

KW - Minocycline

KW - MMP-9

UR - http://www.scopus.com/inward/record.url?scp=84880746947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880746947&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.36023

DO - 10.1002/ajmg.a.36023

M3 - Article

C2 - 23824974

AN - SCOPUS:84880746947

VL - 161

SP - 1897

EP - 1903

JO - American Journal of Medical Genetics

JF - American Journal of Medical Genetics

SN - 1552-4825

IS - 8

ER -